摘要
目的观察重组人血管内皮抑制素(恩度)联合化疗治疗除肺癌外晚期恶性肿瘤的临床疗效和毒副反应。方法经病理组织学或细胞学检查确诊的Ⅳ期恶性肿瘤患者22例,其中大肠癌7例,宫颈癌6例,胰腺癌5例,胃癌2例,鼻腔NK/T细胞淋巴瘤1例,腹膜转移性腺癌1例,其中恩度15mg/d静脉滴注,连续14天,每21天为1周期。同时联合既往未使用的或与既往治疗无交叉耐药的化疗药物。结果 22例患者PR8例(占36.4%),SD10例(占45.5%),PD4例(占18.2%),RR36.4%,DCR81.8%。QOL的改善稳定率90.9%;不良反应较少见且程度多数较轻。结论恩度联合化疗治疗晚期恶性肿瘤患者疗效较好,临床耐受性好,能改善患者生活质量,值得临床上推广应用。
Objective To observe the the clinical efficacy and toxicity of recombinant human endostatin combined with chemotherapy for advanced cancer except lung cancer.Methods Pathology or cytology confirmed 22 cases of stage Ⅳ cancer patients,including 7 cases of colorectal cancer,6 cases of cervical cancer,5 cases of pancreatic cancer,2 cases of gastric cancer,1 cases of nasal NK /T cell lymphoma,1 case of peritoneal metastatic adenocarcinoma,which Endostar 15mg /d intravenous drip,continuous 14d,every 21 days as a cycle.At the same time combined with the chemotherapy which previous unused or past treatment without cross-resistance.Results 22 patients with PR 8 cases（36.4%）,SD 10 cases（45.5%）,PD 4 cases（18.2%）,RR 36.4%,DCR 81.8%.Steady rate of improvement of QOL was 90.9%;adverse reactions rare and the majority of lesser degree.Conclusion Endostar combined with chemotherapy in treating advanced cancer patients with good effect,good clinical tolerance,can improve the quality of life of patients,should be clinical application.
出处
《中国老年保健医学》
2010年第5期21-23,共3页
Chinese Journal of Geriatric Care
